Navigation Links
Translational Sciences Corporation to Launch OncoTrac™ at the American Society of Clinical Oncology (ASCO) Annual Meeting
Date:6/1/2011

BOSTON and CHICAGO, June 1, 2011 /PRNewswire/ -- Translational Sciences Corp. (TSC) will launch OncoTracfor Clinical Research at the America Society of Clinical Oncology (ASCO), June 4-6, at Chicago's McCormick Place, Booth #22114. The OncoTrac™ family of software products provides a structured workflow solution for clinicians to report precise measurement of solid and metastatic tumor progression.

OncoTrac™ for Clinical Research enterprise software facilitates tumor response assessment using widely accepted standards such as RECIST 1.0, RECIST 1.1, and WHO, as well as emerging standards such as the Choi criteria. Assessments using these criteria are commonly required by clinical trial protocols and are often submitted as primary and secondary end-point data in new anti-cancer FDA drug approval applications. Yet, not all clinical cancer research reports tumor response correctly with regard to these standards. OncoTrac™is designed to assure conformity to these standards and aid compliance with established clinical research standards including FDA Good Clinical Practice (GCP) and Part 11 Electronic Medical Records. Subject assessment data are integrated into existing research workflows, thereby providing capabilities comparable to those performed at core imaging laboratories in support of drug applications.

Medical imaging techniques such as CT and MRI produce very large data sets that are typically displayed as images and read by clinicians. Often times, subtle but clinically significant findings can be difficult to visualize and computational analysis has been demonstrated to assist precise identification or measurement of disease. The routine implementation of RECIST as a research standard is a clear example,” said Howard Pinsky, CEO of Translational Sciences Corp.  
'/>"/>

SOURCE Translational Sciences Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics
2. Janet Hammond Joins Roche as Vice President, Translational Medicine - Virology
3. AndroScience Corporation Awarded a $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH to Develop an Oral Treatment for Spinal Bulbar Muscular Atrophy (Kennedys Disease)
4. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
5. Childrens Hospital Boston and Particle Sciences Cooperate on Translational Medicine Efforts
6. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
7. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
8. CTMM Becomes One of the Worlds Largest Public-Private Partnerships in Translational Medical Research
9. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
10. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
11. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 STAAR Surgical ... manufacturer and marketer of implantable lenses and delivery systems ... quarter ended July 4, 2014 of $20.0 million, a ... quarter of 2013. On a constant currency basis, revenues ... to the second quarter of 2013.  The effect of ...
(Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
(Date:7/31/2014)... 2014  UBM Medica US announces that ... oncologists, presents exclusive slide shows dealing with communication in ... cancer care. Cancer Network, the ... news, blogs, and podcasts about the latest clinical findings. ... , End-of-life care is challenging for even ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6
... SANTA BARBARA, Calif., Dec. 6, 2010 Direct ... has donated critically needed medical supplies to assist cholera ... University Hospital (JUH) in Cap-Haitien. JUH is the main public ... I.V. solutions and supplies will also be distributed to the ...
... DIEGO, Dec. 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, ... of their first-in-class CK2 inhibitor at the 52nd Annual Meeting ... on December 4-7 in Orlando, FL, the company announced today. ... on targeting CK2, a protein kinase that is essential for ...
Cached Medicine Technology:CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 2CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 3Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 2Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 3
(Date:8/1/2014)... August 01, 2014 Stryker hip ... of the 2012 Rejuvenate and ABG II Modular-Neck ... New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... proceeding, the Court has issued a Final ... and all hard copy and electronic materials produced ...
(Date:8/1/2014)... Almost 140 people die every year in accidents ... But there are several simple ways to ... coordinator at Cincinnati Children,s Hospital Medical Center,s Comprehensive ... news release. "As families begin to prepare ... parents and children to go over school bus ...
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly experienced ... of power morcellators in gynecological surgeries, Bernstein Liebhard LLP ... to withdraw a number of power morcellators marketed by ... a report from The New York Times, some critics ...
(Date:8/1/2014)... Las Vegas, NV (PRWEB) August 01, 2014 ... issues and opportunities for independent community pharmacies. At ... tradeshow, pharmacists are equipped with practices and resources ... General Session, AmerisourceBergen leaders focused on critical issues ... to learn, optimize and grow. , ThoughtSpot ...
(Date:8/1/2014)... NY, August 1, 2014Lesbian, gay, bisexual, and transgender individuals ... same problems as some of their heterosexual and cisgendered ... often face additional physiological and legal challenges to ... advances in assisted reproduction options is presented in the ... Possibilities ," published in LGBT Health ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Expert Offers School Bus Safety Tips 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2
... 9, 2010) An ultra-low-molecular-weight heparin called semuloparin ... venous thromboembolism in orthopedic surgery patients in a ... committee chaired by McMaster University professor Dr. Alexander ... completed international clinical studies on short-term venous thromboembolism ...
... ... ... bliss is not all it’s cracked up to be. Oh, sure, it’s great while it ... of July sparkler. , , ,Long-lasting, transformational marriages rely on more than passion to thrive, ...
... ... Khoi Nguyen and Dennis McDowell have joined their executive sales staff in the Houston ... the area,s most influential hospitals and providers. Accel is the Company’s top tier network ... providers. , ...
... BUENOS AIRES, ARGENTINA, July 9 Pfizer Inc, the ... of a number of hemophilia studies will be presented ... taking place July 10-14, 2010, in Buenos Aires, Argentina. ... Xa as a potential new approach to restoring hemostasis, ...
... ... nation to receive the “Best Practice” award from Safety Net Solutions. The award recognizes the ... for the communities they serve. , ... (Vocus) July 8, 2010 -- St. Elizabeth’s Dental Clinic is one ...
... ... health problems, Sam’s Club is hosting free health screenings in more than 400 of its ... ... To help its members and community residents detect a range of preventable health problems, Sam’s ...
Cached Medicine News:Health News:Drug study shows improvement in major orthopedic surgery care 2Health News:When the Fireworks Fizzle: How to Stoke the Flames of Lasting Love 2Health News:HealthSmart Adds Experienced Professionals to Houston Sales Force 2Health News:Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress 2Health News:St. Elizabeth Dental Clinic Named one of the Best in the Nation 2Health News:Sam's Club Hosts Health Screenings July 10 2
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... are liquid controls designed to ... procedures that detect Chlamydia trachomatis ... are specimen specific, they can ... or endocervical/urethral swabs throughout the ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: